Pliant TherapeuticsJP Morgan 2025.pdf

1、 2025 PLIANT THERAPEUTICSDeveloping Novel Treatments for Fibrotic DiseasesJ.P.MORGAN HEALTH CARE CONFERENCEJanuary 2025 2025 PLIANT THERAPEUTICSDisclaimersThis presentation has been prepared by Pliant Therapeutics,Inc.(we,us,our,Pliant or the“Company”).The information set forth herein does not purpo

2、rt to be complete or to contain all of the information you may desire.Statements contained herein are made as of the date of this presentation unless stated otherwise,and this presentation shall not under any circumstances create an implication that the information contained herein is correct as of

3、any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.This presentation includes forward-looking statements regarding Pliants proprietary drug candidates,the timing of the start an

4、d conclusion of ongoing or planned clinical trials,including the timing of,and our ability to achieve,anticipated milestones,the sufficiency of our cash,cash equivalents and short-term investments,the timing and outcome of regulatory decisions,future availability of clinical trial data,our collabora

5、tions for our product candidates and the maintenance of those collaborations;business and results from operations;and other matters.Actual results could differ materially from those contained in any forward-looking statements as a result of various factors,including without limitation:that Pliants d

6、rug candidates do not advance in development or result in approved products on a timely or cost effective basis or at all;the cost,timing and results of clinical trials;our ability to manage and mitigate the impact of the ongoing COVID-19 pandemic;that many drug candidates that have completed early-